Floatz logo

Jnj-40411813

Confusion

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

13 Active assets in the Confusion cohort.

Asset / SponsorPhaseRating
PROPOFOL
RenJi Hospital
Phase 4BB
ISOFLURANE
Duke University
Phase 4BB
.GAMMA.-CYCLODEXTRIN, 6A,6B,6C,6D,6E,7F,6G,6H-OCTAKIS-S-(2-CARBOXYETHYL)-6A,6B,6C,6D,6E,7F,6G,6H-OCTATHIO-
Konkuk University Medical Center
Phase 4BB
Pyridostigmine
Konkuk University Medical Center
Phase 4BB
Clonidine
Insel Gruppe AG, University Hospital Bern
Phase 4BB

View all 23 →

Same molecule, other indications

Jnj-40411813 is also rated in:

focal epilepsyDormant
B
Indicative ·
57 / 100
View asset →
schizophreniaDormant
CCC
Indicative ·
55 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →